Using cimetidine to mitigate cisplatin-induced ototoxicity

Area of Science:

• Ototoxicity research
• Pharmacology
• Cancer therapeutics

Background:

• Cisplatin is a vital chemotherapy drug, but its use is limited by ototoxicity (inner ear damage).
• Organic cation transporter 2 (OCT2) facilitates cisplatin entry into inner ear cells, contributing to ototoxicity.
• Cimetidine is an FDA-approved drug known to inhibit OCT2 activity.

Purpose of the Study:

• To investigate if cimetidine can prevent cisplatin-induced ototoxicity by inhibiting OCT2.
• To assess if this protective effect impacts cisplatin's efficacy against cancer cells.

Main Methods:

• Utilized House Ear Institute-Organ of Corti 1 (HEI-OC1) cell line to model inner ear cells.
• Assessed cell viability after exposure to cisplatin and cimetidine.
• Evaluated the combined effect of cisplatin and cimetidine on cancer cell lines.

Main Results:

• Cisplatin reduced HEI-OC1 cell viability in a dose-dependent manner.
• Cimetidine counteracted cisplatin-induced ototoxicity in HEI-OC1 cells.
• Cimetidine did not interfere with cisplatin's cytotoxic effects on cancer cells.

Conclusions:

• Inhibiting OCT2 with cimetidine shows promise in mitigating cisplatin-induced ototoxicity.
• Combined therapy may offer a strategy to reduce hearing loss in cancer patients undergoing cisplatin treatment.
• This approach could improve the therapeutic index of cisplatin chemotherapy.